Advertisement
Journal of Hepatology
EASL
Advanced searchSave search
Letter to the Editor| Volume 78, ISSUE 2, e61-e63, February 2023

Life’s Essential 8 and MAFLD in the United States

  • Xinyu Wang
    Affiliations
    Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China
    Search for articles by this author
  • Aruna Wang
    Affiliations
    Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China
    Search for articles by this author
  • Ruosu Zhang
    Affiliations
    Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China
    Search for articles by this author
  • Si Cheng
    Affiliations
    Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China
    Search for articles by this author
  • Yuanjie Pang
    Correspondence
    Corresponding author. Address: Dept. of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing, 100191, China. Tel.: 86-010-82801528, fax: 86-010-82801530.
    Affiliations
    Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China
    Search for articles by this author
Published:October 25, 2022DOI:https://doi.org/10.1016/j.jhep.2022.10.014
Life’s Essential 8 and MAFLD in the United States
Previous ArticleCases of severe acute liver injury following inactivated SARS-CoV-2 vaccination
Next ArticleAssessing causal relationship between non-alcoholic fatty liver disease and risk of atrial fibrillation
      The American Heart Association (AHA) recently proposed Life’s Essential 8 (LE8) as an update of Life’s Simple 7 (LS7) to quantify cardiovascular health (CVH), which included five health behaviors (nicotine exposure, physical activity, diet, body mass index, and sleep health) and three health factors (blood lipids, blood pressure, and blood glucose).
      • Lloyd-Jones D.M.
      • Allen N.B.
      • Anderson C.A.M.
      • Black T.
      • Brewer L.C.
      • Foraker R.E.
      • et al.
      Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association.
      Circulation. 2022; 146
      By adding a new sleep metric and being redefined on a more continuous scale, LE8 better reflects recent clinical guidelines, interindividual difference and intraindividual change than LS7.
      • Lloyd-Jones D.M.
      • Allen N.B.
      • Anderson C.A.M.
      • Black T.
      • Brewer L.C.
      • Foraker R.E.
      • et al.
      Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association.
      Circulation. 2022; 146
      Previous studies have reported associations between LS7 and cardiometabolic disease (e.g., cardiovascular disease [CVD] and diabetes).
      • Fretts A.M.
      • Howard B.V.
      • McKnight B.
      • Duncan G.E.
      • Beresford S.A.A.
      • Mete M.
      • et al.
      Life’s Simple 7 and incidence of diabetes among American Indians: the strong Heart family study.
      Diabetes Care. 2014; 37: 2240-2245
      ,
      • Younus A.
      • Aneni E.C.
      • Spatz E.S.
      • Osondu C.U.
      • Roberson L.
      • Ogunmoroti O.
      • et al.
      A systematic review of the prevalence and outcomes of ideal cardiovascular health in US and Non-US populations.
      Mayo Clin Proc. 2016; 91: 649-670
      Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly proposed nomenclature that has been reported to be associated with increased all-cause and cardiovascular mortality, and those with advanced fibrosis have higher risk of all-cause mortality compared to those without.
      • Kim D.
      • Konyn P.
      • Sandhu K.K.
      • Dennis B.B.
      • Cheung A.C.
      • Ahmed A.
      Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
      J Hepatol. 2021; 75: 1284-1291
      Since MAFLD shared similar lifestyle and metabolic risk factors with CVD, we aimed to investigate the associations of LE8 with MAFLD and clinically significant fibrosis (CSF) in participants with MAFLD.

      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Lloyd-Jones D.M.
        • Allen N.B.
        • Anderson C.A.M.
        • Black T.
        • Brewer L.C.
        • Foraker R.E.
        • et al.
        Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association.
        Circulation. 2022; 146
        View in Article
        • Fretts A.M.
        • Howard B.V.
        • McKnight B.
        • Duncan G.E.
        • Beresford S.A.A.
        • Mete M.
        • et al.
        Life’s Simple 7 and incidence of diabetes among American Indians: the strong Heart family study.
        Diabetes Care. 2014; 37: 2240-2245
        View in Article
        • Younus A.
        • Aneni E.C.
        • Spatz E.S.
        • Osondu C.U.
        • Roberson L.
        • Ogunmoroti O.
        • et al.
        A systematic review of the prevalence and outcomes of ideal cardiovascular health in US and Non-US populations.
        Mayo Clin Proc. 2016; 91: 649-670
        View in Article
        • Kim D.
        • Konyn P.
        • Sandhu K.K.
        • Dennis B.B.
        • Cheung A.C.
        • Ahmed A.
        Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
        J Hepatol. 2021; 75: 1284-1291
        View in Article
        • Vilar-Gomez E.
        • Nephew L.D.
        • Vuppalanchi R.
        • Gawrieh S.
        • Mladenovic A.
        • Pike F.
        • et al.
        High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population.
        Hepatology. 2021; 75: 1491-1506
        View in Article
        • Eslam M.
        • Sanyal A.J.
        • George J.
        • Sanyal A.
        • Neuschwander-Tetri B.
        • Tiribelli C.
        • et al.
        MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.
        Gastroenterology. 2020; 158: 1999-2014
        View in Article
        • DeCoste L.R.
        • Wang N.
        • Palmisano J.N.
        • Palmisano J.N.
        • Mendez J.
        • Hoffmann U.
        • et al.
        Adherence to ideal cardiovascular health metrics is associated with reduced odds of hepatic steatosis.
        Hepatol Commun. 2020; 5: 74-82
        View in Article
        • Oni E.
        • Ogunmoroti O.
        • Allen N.
        • A-Mallah M.H.
        • Blankstein R.
        • Martin S.S.
        • et al.
        Life's Simple 7 and nonalcoholic fatty liver disease: the Multiethnic Study of Atherosclerosis.
        Am J Med. 2021; 134: 519-525
        View in Article
        • Angell S.Y.
        • McConnell M.V.
        • Anderson C.A.M.
        • Bibbins-Domingo K.
        • Boyle D.S.
        • Capewell S.
        • et al.
        The American Heart Association 2030 impact goal: a presidential advisory from the American Heart Association.
        Circulation. 2020; 141
        View in Article

      Article info

      Publication history

      Published online: October 25, 2022
      Accepted: October 10, 2022
      Received: October 5, 2022

      Identification

      DOI: https://doi.org/10.1016/j.jhep.2022.10.014

      Copyright

      © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX